Skip to main content Accessibility help
×
Home

Hypofractionated volumetric modulated arc therapy with SIB adjuvant to breast preservation surgery: retrospective experience from a Regional Cancer Centre in Eastern India

  • Ashwin Mohandas Pallath (a1), Debarshi Lahiri (a1), Biplab Misra (a1), Sanjoy Roy (a1), Tapas Maji (a1), Dilip Kumar Ray (a2) and Dillip Kumar Misra (a2)...

Abstract

Background:

The incidence of breast cancer has surpassed cervical cancer in India and it has now become the most common cancer in women. Multiple randomised studies have reported low α/β value in the range of 3–4 for breast cancer, which predict a potential radiobiological advantage for hypofractionated radiotherapy resulting in such schedules becoming standard in many centers with reduction in overall treatment time. Volumetric modulated arc therapy (VMAT) is a novel technique of delivering radiotherapy that reduces treatment delivery time, requires less monitor units (MU) and offers good conformity. The mean dose to normal tissue may be minimised using this technique although there will be inferior sparing if we consider the low-dose volume such as V5, the effect of which is not quantifiable yet.

Aim:

Reporting acute toxicity, cosmetic effects, and quality of life in patients of early breast cancer treated with adjuvant hypofractionated VMAT with SIB.

Material and Methods:

The records of 44 patients registered at the hospital between August 2014 and December 2015 were included in this analysis. Acute toxicities were analysed using CTCAE v4.03. Cosmetic outcomes were assessed using Harvard scale, while quality of life outcomes were assessed using EORTC scales and Health Related quality of life (HRQOL) questionnaires (QLQ-C30 and QLQ-BR23).

Results:

No grade ≥2 skin toxicities were recorded. Breast pain was recorded as Grade 1 in 13·8% patients and Grade 1 fatigue in 18·2%. The maximum haematological abnormality grade recorded was Grade 1. Cosmesis was assessed at the baseline, 6 months, 1 year and 2 years. A total of 88·6% of the patients had an Excellent or good cosmesis at the baseline, which was similar even at 6 months, at 88·7%, improved further at 1 year to 90·9%. At 6 months post radiotherapy, high functional scale QOL scores were noted.

Conclusion:

The technique is associated with minimum acute toxicity, good to excellent cosmesis and acceptable quality of life.

Copyright

Corresponding author

Author for correspondence: Debarshi Lahiri, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, 700026, India. E-mail: debarshil@gmail.com

References

Hide All
1.Bray, F, Ferlay, J, Soerjomataram, I, Siegel, R, Torre, L, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394424.10.3322/caac.21492
2.Clarke, M, Collins, R, Darby, S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): 20872106. doi: 10.1016/S01406736(05)67887-7.
3.Yarnold, J, Ashton, A, Bliss, J et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol 2005; 75 (1): 917. doi: 10.1016/j.radonc.2005.01.005.
4.START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9 (4): 331341. doi: 10.1016/S1470-2045(08)70077-9.
5.Hennequin, C, Dubray, B. [Alpha/beta ratio revisited in the era of hypofractionation]. Cancer Radiother 2013; 17 (5–6): 344348. doi: 10.1016/jcanrad.2013.06.035.
6.Owen, J R, Ashton, A, Bliss, J M et al. Effect of radiotherapy fraction size on tumour control in patients with early stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7 (6): 467471. doi: 10.1016/S14702045(06)70699-4.
7.START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371 (9618): 10981107. doi: 10.1016/S0140-6736(08)60348-7.
8.Whelan, T J, Pignol, J P, Levine, M N et al. Long- term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362 (6): 513520. doi: 10.1056/NEJMoa0906260.
9.Borghero, Y O, Salehpour, M, McNeese, M D et al. Multileaf field-in-field forward- planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison. Radiother Oncol 2007; 82 (3): 324328. doi: 10.1016/j.radonc.2006.10.011.
10.Teh, A Y, Walsh, L, Purdie, T G et al. Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy-a feasibility and toxicity study. Radiother Oncol 2012; 102 (1): 8995. doi: 10.1016/j.radonc.2011.10.015.
11.Scorsetti, M, Alongi, F, Fogliata, A et al. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiat Oncol 2012; 7 (1): 145. doi: 10.1186/1748-717X-7-145.
12.Teoh, M, Clark, C H, Wood, K, Whitaker, S, Nisbet, A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84 (1007): 967996. doi: 10.1259/bjr/22373346.
13.White, J, Tai, A, Arthur, D et al. Breast cancer atlas for radiation therapy planning: consensus definitions. Radiat Ther Oncol Group, 2011. http://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx.
15.EORTC– Quality of Life. Quality of life of cancer patients | EORTC – quality of life, 2019. https://qol.eortc.org/questionnaire/eortc-qlq-c30.
16.EORTC– Quality of Life. Breast cancer (update of QLQ-BR23) | EORTC – quality of life, 2019. https://qol.eortc.org/questionnaire/update-qlq-br23.
17.Formenti, S C, Gidea-Addeo, D, Goldberg, J D et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007; 25 (16): 22362242. doi: 10.1200/JCO.2006.09.1041.
18.Chadha, M, Vongtama, D, Friedmann, P et al. Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 2012; 12 (1): 5762. doi: 10.1016/j.clbc.2011.09.002.
19.Goldstein, D, Bennett, B K, Webber, K et al. Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. J Clin Oncol 2012; 30 (15): 18051812. doi: 10.1200/JCO.2011.34.6148.
20.Jagsi, R, Griffith, K A, Boike, T P et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol 2015; 1 (7): 918930. doi: 10.1001/jamaoncol.2015.2590.
21.Harris, J R, Levene, M B, Svensson, G, Hellman, S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 1979; 5 (2): 257261. doi: 10.1016/03603016(79)90729-6.
22.McDonald, M W, Godette, K D, Whitaker, D J, Davis, L W, Johnstone, P A S. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77 (2): 523530. doi: 10.1016/j.ijrobp.2009.05.042.
23.Ghannam, A A, Khedr, R A. An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity. J Egypt Natl Canc Inst 2016; 28 (1): 3944. doi: 10.1016/j.jnci.2016.01.002.
24.Fayers, P M, Aaronson, N K, Bjordal, K et al. The EORTC QLQ-C30 Scoring Manual, 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
25.Mock, V, Dow, K H, Meares, C J et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997; 24 (6): 9911000.
26.Versmessen, H, Vinh-Hung, V, Van Parijs, H et al. Health-related quality of life in survivors of stage I-II breast cancer: randomised trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer 2012; 12 (1): 495.10.1186/1471-2407-12-495

Keywords

Hypofractionated volumetric modulated arc therapy with SIB adjuvant to breast preservation surgery: retrospective experience from a Regional Cancer Centre in Eastern India

  • Ashwin Mohandas Pallath (a1), Debarshi Lahiri (a1), Biplab Misra (a1), Sanjoy Roy (a1), Tapas Maji (a1), Dilip Kumar Ray (a2) and Dillip Kumar Misra (a2)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed